Nadine Al-Naamani1,2,3, Harold I Palevsky4, David J Lederer5, Evelyn M Horn6, Stephen C Mathai7, Kari E Roberts1, Russell P Tracy8, Paul M Hassoun7, Reda E Girgis9, Daichi Shimbo10, Wendy S Post11,12, Steven M Kawut4,13. 1. 1 Department of Medicine, Tufts Medical Center, Boston, Massachusetts. 2. 2 Tufts Clinical and Translational Science Institute, Boston, Massachusetts. 3. 3 Sackler School of Graduate Biomedical Sciences, Tufts University, Boston, Massachusetts. 4. 4 Department of Medicine, and. 5. 5 Department of Medicine, College of Physicians and Surgeons, and. 6. 6 Department of Medicine, Weill-Cornell Medical School, New York, New York. 7. 7 Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland. 8. 8 College of Medicine, University of Vermont, Colchester, Vermont. 9. 9 Richard DeVos Heart and Lung Transplant Services, Spectrum Health Hospitals, Grand Rapids, Michigan; and. 10. 10 Center for Behavioral Cardiovascular Health, Department of Medicine, Columbia University, New York, New York. 11. 11 Department of Medicine, and. 12. 12 Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland. 13. 13 Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania.
Abstract
RATIONALE: Pulmonary arterial hypertension (PAH) is a rare progressive disease of the pulmonary vasculature that is characterized by endothelial dysfunction, inflammation, and right ventricular dysfunction. OBJECTIVES: The main objective was to determine whether endothelial, inflammatory, and cardiac biomarkers would be associated with the World Health Organization functional assessment and survival in patients with PAH. METHODS: We performed a retrospective cohort study of patients with PAH enrolled in the Randomized Clinical Trial of Aspirin and Simvastatin for Pulmonary Arterial Hypertension (ASA-STAT). Biomarkers (N-terminal fragment of pro-BNP [NT-pro-BNP], von Willebrand factor [vWF], soluble P selectin, C-reactive protein, total and high-density lipoprotein cholesterol, triglycerides, tumor necrosis factor, IL-6, β-thromboglobulin, and thromboxane B2) were measured at baseline. Patients from the study were followed until lung transplantation, death, or August 1, 2013. Ordinal logistic regression and Cox regression analyses were performed. MEASUREMENTS AND MAIN RESULTS:Sixty-five patients with PAH were enrolled. The mean age was 51 years, and 86% were women. Higher vWF activity, lower high-density lipoprotein cholesterol, and higher thromboxane B2 levels were associated with worse World Health Organization functional class after adjustment for age, sex, and etiology of PAH. Higher NT-pro-BNP levels, lower vWF activity, and lower total cholesterol were associated with an increased risk of death or lung transplant after adjustment for age, sex, etiology of PAH, and 6-minute-walk distance. CONCLUSIONS: In patients with PAH, lower vWF activity and cholesterol levels and higher NT-pro-BNP levels at baseline were associated with an increased risk of death or transplantation. Clinical trial registered with www.clinicaltrials.gov (NCT00384865).
RCT Entities:
RATIONALE: Pulmonary arterial hypertension (PAH) is a rare progressive disease of the pulmonary vasculature that is characterized by endothelial dysfunction, inflammation, and right ventricular dysfunction. OBJECTIVES: The main objective was to determine whether endothelial, inflammatory, and cardiac biomarkers would be associated with the World Health Organization functional assessment and survival in patients with PAH. METHODS: We performed a retrospective cohort study of patients with PAH enrolled in the Randomized Clinical Trial of Aspirin and Simvastatin for Pulmonary Arterial Hypertension (ASA-STAT). Biomarkers (N-terminal fragment of pro-BNP [NT-pro-BNP], von Willebrand factor [vWF], soluble P selectin, C-reactive protein, total and high-density lipoprotein cholesterol, triglycerides, tumornecrosis factor, IL-6, β-thromboglobulin, and thromboxane B2) were measured at baseline. Patients from the study were followed until lung transplantation, death, or August 1, 2013. Ordinal logistic regression and Cox regression analyses were performed. MEASUREMENTS AND MAIN RESULTS: Sixty-five patients with PAH were enrolled. The mean age was 51 years, and 86% were women. Higher vWF activity, lower high-density lipoprotein cholesterol, and higher thromboxane B2 levels were associated with worse World Health Organization functional class after adjustment for age, sex, and etiology of PAH. Higher NT-pro-BNP levels, lower vWF activity, and lower total cholesterol were associated with an increased risk of death or lung transplant after adjustment for age, sex, etiology of PAH, and 6-minute-walk distance. CONCLUSIONS: In patients with PAH, lower vWF activity and cholesterol levels and higher NT-pro-BNP levels at baseline were associated with an increased risk of death or transplantation. Clinical trial registered with www.clinicaltrials.gov (NCT00384865).
Entities:
Keywords:
World Health Organization functional class; biomarkers; pulmonary arterial hypertension; survival
Authors: Jean-Luc Cracowski; José Labarère; Jean-Charles Renversez; Bruno Degano; François Chabot; Marc Humbert Journal: Am J Respir Crit Care Med Date: 2012-07-01 Impact factor: 21.405
Authors: Stuart D Katz; Katarzyna Hryniewicz; Ingrid Hriljac; Kujtim Balidemaj; Clarito Dimayuga; Alhakam Hudaihed; Aleksandr Yasskiy Journal: Circulation Date: 2005-01-17 Impact factor: 29.690
Authors: Yongmei Liu; Josef Coresh; Joseph A Eustace; J Craig Longenecker; Bernard Jaar; Nancy E Fink; Russell P Tracy; Neil R Powe; Michael J Klag Journal: JAMA Date: 2004-01-28 Impact factor: 56.272
Authors: Robert P Frantz; Harrison W Farber; David B Badesch; C Greg Elliott; Adaani E Frost; Michael D McGoon; Carol Zhao; David R Mink; Mona Selej; Raymond L Benza Journal: Chest Date: 2018-01-31 Impact factor: 9.410
Authors: Magdalena Rysz-Górzynska; Anna Gluba-Brzózka; Amirhossein Sahebkar; Maria-Corina Serban; Dimitri P Mikhailidis; Sorin Ursoniu; Peter P Toth; Vera Bittner; Gerald F Watts; Gregory Y H Lip; Jacek Rysz; Alberico L Catapano; Maciej Banach Journal: Sci Rep Date: 2016-07-22 Impact factor: 4.379